Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Davies, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Focus on glycaemic management: A veritable feast or a dog's dinner?

Melanie Davies

Medicine Department of Cardiovascular Sciences, University of Leicester, melanie.davies{at}uhl-tr.nhs.uk

The latest National Institute for Health and Clinical Excellence guideline was published in May 2008. Despite the availability of several new pharmacological interventions for the treatment of type 2 diabetes since the previous guidance in 2002, the incretin mimetic exenatide is the only newer agent included in the new guideline. Herein, the key priorities around glycaemic management are reviewed and consideration is given to whether the guideline is likely to have major implications for management of people with type 2 diabetes. Br J Diabetes Vasc Dis 2008; 8: 191—194

Key Words: exenatide • guidelines • NICE • thiazolidinediones • type 2 diabetes

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 4, 191-194 (2008)
DOI: 10.1177/1474651408094886
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
S. H Song and T. A Gray
Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008
The British Journal of Diabetes & Vascular Disease, March 1, 2009; 9(2): 69 - 74.
[Abstract] [PDF]